Paclitaxel in colon cancer management: from conventional chemotherapy to advanced nanocarrier delivery systems.

IF 3.1 4区医学 Q2 PHARMACOLOGY & PHARMACY Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2024-12-01 Epub Date: 2024-07-11 DOI:10.1007/s00210-024-03256-8

Komal, Bibhu Prasad Nanda, Lovekesh Singh, Rohit Bhatia, Amandeep Singh

{"title":"Paclitaxel in colon cancer management: from conventional chemotherapy to advanced nanocarrier delivery systems.","authors":"Komal, Bibhu Prasad Nanda, Lovekesh Singh, Rohit Bhatia, Amandeep Singh","doi":"10.1007/s00210-024-03256-8","DOIUrl":null,"url":null,"abstract":"<p><p>Paclitaxel, a potent chemotherapeutic agent derived from the bark of the Pacific yew tree, has demonstrated significant efficacy in the treatment of various cancers, including colon cancer. This comprehensive review delves into the conventional treatments for colon cancer, emphasizing the crucial role of paclitaxel in contemporary management strategies. It explores the intricate process of sourcing and synthesizing paclitaxel, highlighting the importance of its structural properties in its anticancer activity. The review further elucidates the mechanism of action of paclitaxel, its pharmacological effects, and its integration into chemotherapy regimens for colon cancer. Additionally, novel drug delivery systems, such as nanocarriers, liposomes, nanoparticles, microspheres, micelles, microemulsions, and niosomes, are examined for their potential to enhance the therapeutic efficacy of paclitaxel. The discussion extends to recent clinical trials and patents, showcasing advancements in paclitaxel formulations aimed at improving treatment outcomes. The review concludes with prospects in the field underscoring the ongoing innovation and potential breakthroughs in colon cancer therapy.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":"9449-9474"},"PeriodicalIF":3.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-024-03256-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Paclitaxel, a potent chemotherapeutic agent derived from the bark of the Pacific yew tree, has demonstrated significant efficacy in the treatment of various cancers, including colon cancer. This comprehensive review delves into the conventional treatments for colon cancer, emphasizing the crucial role of paclitaxel in contemporary management strategies. It explores the intricate process of sourcing and synthesizing paclitaxel, highlighting the importance of its structural properties in its anticancer activity. The review further elucidates the mechanism of action of paclitaxel, its pharmacological effects, and its integration into chemotherapy regimens for colon cancer. Additionally, novel drug delivery systems, such as nanocarriers, liposomes, nanoparticles, microspheres, micelles, microemulsions, and niosomes, are examined for their potential to enhance the therapeutic efficacy of paclitaxel. The discussion extends to recent clinical trials and patents, showcasing advancements in paclitaxel formulations aimed at improving treatment outcomes. The review concludes with prospects in the field underscoring the ongoing innovation and potential breakthroughs in colon cancer therapy.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

紫杉醇在结肠癌治疗中的应用：从传统化疗到先进的纳米载体给药系统。

紫杉醇是一种从太平洋紫杉树皮中提取的强效化疗药物，在治疗包括结肠癌在内的多种癌症方面具有显著疗效。本综述深入探讨了结肠癌的传统治疗方法，强调了紫杉醇在当代治疗策略中的关键作用。综述探讨了紫杉醇来源和合成的复杂过程，强调了其结构特性在抗癌活性中的重要性。综述进一步阐明了紫杉醇的作用机制、药理作用以及将其纳入结肠癌化疗方案的情况。此外，还研究了新型给药系统，如纳米载体、脂质体、纳米颗粒、微球、胶束、微乳液和纳米体等，以探讨它们提高紫杉醇疗效的潜力。讨论延伸到最近的临床试验和专利，展示了旨在改善治疗效果的紫杉醇制剂的进展。综述最后介绍了该领域的发展前景，强调了结肠癌治疗领域的持续创新和潜在突破。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Naunyn-Schmiedeberg's archives of pharmacology 医学-药学

CiteScore

6.20

自引率

5.60%

发文量

142

审稿时长

4-8 weeks

期刊介绍： Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.